Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 1/2011

01-01-2011

NADPH oxidases and cardiac remodelling

Authors: Adam Nabeebaccus, Min Zhang, Ajay M. Shah

Published in: Heart Failure Reviews | Issue 1/2011

Login to get access

Abstract

A heart under chronic stress undergoes cardiac remodelling, a process that comprises structural and functional changes including cardiomyocyte hypertrophy, interstitial fibrosis, contractile dysfunction, cell death and ventricular dilatation. Reactive oxygen species (ROS)-dependent modulation of intracellular signalling is implicated in the development of cardiac remodelling. Among the different ROS sources that are present in the heart, NADPH oxidases (NOXs) are particularly important in redox signalling. NOX isoforms are expressed in multiple cell types including cardiomyocytes, fibroblasts, endothelial cells and inflammatory cells—with the two main isoforms expressed in the heart being NOX2 and NOX4. Recent studies indicate that NOX-dependent signalling is involved in the development of cardiomyocyte hypertrophy, interstitial fibrosis and post-MI remodelling. NOXs may also be involved in the genesis of contractile dysfunction and myocyte apoptosis. Here, we review the main effects of NOXs in the pathogenesis of cardiac remodelling and the redox-sensitive signalling pathways that underlie these effects. The elucidation of mechanisms involved in NOX-dependent regulation of cardiac remodelling may lead to new therapeutic targets for heart failure.
Literature
1.
Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 35(3):569–582PubMedCrossRef
2.
Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA (2006) Controversies in ventricular remodelling. Lancet 367(9507):356–367PubMedCrossRef
3.
Giordano FJ (2005) Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115(3):500–508PubMed
4.
Takimoto E, Kass DA (2007) Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49(2):241–248PubMedCrossRef
5.
Hori M, Nishida K (2009) Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 81(3):457–464PubMedCrossRef
6.
Droge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82(1):47–95PubMed
7.
Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban E, Hare JM (2001) Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104(20):2407–2411PubMedCrossRef
8.
Ide T, Tsutsui H, Hayashidani S, Kang D, Suematsu N, Nakamura K, Utsumi H, Hamasaki N, Takeshita A (2001) Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 88(5):529–535PubMed
9.
Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, Kass DA (2005) Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 115(5):1221–1231PubMed
10.
Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM (2003) Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41(12):2164–2171PubMedCrossRef
11.
Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM (2006) NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8(5–6):691–728PubMedCrossRef
12.
Babior BM, Lambeth JD, Nauseef W (2002) The neutrophil NADPH oxidase. Arch Biochem Biophys 397(2):342–344PubMedCrossRef
13.
14.
Sumimoto H, Miyano K, Takeya R (2005) Molecular composition and regulation of the nox family NAD(P)H oxidases. Biochem Biophys Res Commun 338(1):677–686PubMedCrossRef
15.
Lambeth JD, Kawahara T, Diebold B (2007) Regulation of nox and duox enzymatic activity and expression. Free Radic Biol Med 43(3):319–331PubMedCrossRef
16.
Brown DI, Griendling KK (2009) Nox proteins in signal transduction. Free Radic Biol Med 47(9):1239–1253PubMedCrossRef
17.
18.
Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG (2006) Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 18(1):69–82PubMedCrossRef
19.
Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Forro L, Schlegel W, Krause KH (2007) NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 406(1):105–114PubMedCrossRef
20.
Dikalov SI, Dikalova AE, Bikineyeva AT, Schmidt HH, Harrison DG, Griendling KK (2008) Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med 45(9):1340–1351PubMedCrossRef
21.
Anilkumar N, Sirker A, Shah AM (2009) Redox sensitive signaling pathways in cardiac remodeling, hypertrophy and failure. Front Biosci 14:3168–3187PubMedCrossRef
22.
Nakagami H, Takemoto M, Liao JK (2003) NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 35(7):851–859PubMedCrossRef
23.
Xiao L, Pimentel DR, Wang J, Singh K, Colucci WS, Sawyer DB (2002) Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol 282(4):C926–C934PubMed
24.
Li JM, Gall NP, Grieve DJ, Chen M, Shah AM (2002) Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40(4):477–484PubMedCrossRef
25.
Bendall JK, Cave AC, Heymes C, Gall N, Shah AM (2002) Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105(3):293–296PubMedCrossRef
26.
Hingtgen SD, Tian X, Yang J, Dunlay SM, Peek AS, Wu Y, Sharma RV, Engelhardt JF, Davisson RL (2006) Nox2-containing NADPH oxidase and akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy. Physiol Genomics 26(3):180–191PubMedCrossRef
27.
Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK (2006) Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci USA 103(19):7432–7437PubMedCrossRef
28.
Kuster GM, Pimentel DR, Adachi T, Ido Y, Brenner DA, Cohen RA, Liao R, Siwik DA, Colucci WS (2005) Alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on ras. Circulation 111(9):1192–1198PubMedCrossRef
29.
Clerk A, Pham FH, Fuller SJ, Sahai E, Aktories K, Marais R, Marshall C, Sugden PH (2001) Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1. Mol Cell Biol 21(4):1173–1184PubMedCrossRef
30.
Izumiya Y, Kim S, Izumi Y, Yoshida K, Yoshiyama M, Matsuzawa A, Ichijo H, Iwao H (2003) Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. Circ Res 93(9):874–883PubMedCrossRef
31.
Wu S, Gao J, Ohlemeyer C, Roos D, Niessen H, Kottgen E, Gessner R (2005) Activation of AP-1 through reactive oxygen species by angiotensin II in rat cardiomyocytes. Free Radic Biol Med 39(12):1601–1610PubMedCrossRef
32.
Tu VC, Sun H, Bowden GT, Chen QM (2007) Involvement of oxidants and AP-1 in angiotensin II-activated NFAT3 transcription factor. Am J Physiol Cell Physiol 292(4):C1248–C1255PubMedCrossRef
33.
Higuchi Y, Otsu K, Nishida K, Hirotani S, Nakayama H, Yamaguchi O, Matsumura Y, Ueno H, Tada M, Hori M (2002) Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 34(2):233–240PubMedCrossRef
34.
Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, Shah AM (2003) Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 93(9):802–805PubMedCrossRef
35.
Maytin M, Siwik DA, Ito M, Xiao L, Sawyer DB, Liao R, Colucci WS (2004) Pressure overload-induced myocardial hypertrophy in mice does not require gp91phox. Circulation 109(9):1168–1171PubMedCrossRef
36.
Touyz RM, Mercure C, He Y, Javeshghani D, Yao G, Callera GE, Yogi A, Lochard N, Reudelhuber TL (2005) Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension 45(4):530–537PubMedCrossRef
37.
Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM (2006) Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 20(9):1546–1548PubMedCrossRef
38.
Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT (2002) Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161(5):1773–1781PubMedCrossRef
39.
Nakamura T, Kataoka K, Fukuda M, Nako H, Tokutomi Y, Dong YF, Ichijo H, Ogawa H, Kim-Mitsuyama S (2009) Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension 54(3):544–551PubMedCrossRef
40.
Yamada T, Nagata K, Cheng XW, Obata K, Saka M, Miyachi M, Naruse K, Nishizawa T, Noda A, Izawa H, Kuzuya M, Okumura K, Murohara T, Yokota M (2009) Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. Eur J Pharmacol 615(1–3):163–170PubMedCrossRef
41.
Westermann D, Riad A, Richter U, Jager S, Savvatis K, Schuchardt M, Bergmann N, Tolle M, Nagorsen D, Gotthardt M, Schultheiss HP, Tschope C (2009) Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol 104(5):499–509PubMedCrossRef
42.
Grieve DJ, Byrne JA, Siva A, Layland J, Johar S, Cave AC, Shah AM (2006) Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload. J Am Coll Cardiol 47(4):817–826PubMedCrossRef
43.
Kandasamy AD, Chow AK, Ali MA, Schulz R (2010) Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 85(3):413–423PubMedCrossRef
44.
Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, Fabbi P, Ballestrero A, Brunelli C, Barsotti A (2006) Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: the role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 69(3):736–745PubMedCrossRef
45.
Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D (2005) NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97(9):900–907PubMedCrossRef
46.
Sakata Y, Chancey AL, Divakaran VG, Sekiguchi K, Sivasubramanian N, Mann DL (2008) Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res Cardiol 103(1):60–68PubMedCrossRef
47.
Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, Lonning S, Ling H, Ertl G, Bauersachs J (2008) Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 103(5):485–492PubMedCrossRef
48.
Hu C, Dandapat A, Sun L, Khan JA, Liu Y, Hermonat PL, Mehta JL (2008) Regulation of TGFbeta1-mediated collagen formation by LOX-1: Studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts. J Biol Chem 283(16):10226–10231PubMedCrossRef
49.
MacCarthy PA, Grieve DJ, Li JM, Dunster C, Kelly FJ, Shah AM (2001) Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation 104(24):2967–2974PubMedCrossRef
50.
Cheng XW, Okumura K, Kuzuya M, Jin Z, Nagata K, Obata K, Inoue A, Hirashiki A, Takeshita K, Unno K, Harada K, Shi GP, Yokota M, Murohara T (2009) Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol 54(1):47–56PubMedCrossRef
51.
Peng T, Lu X, Feng Q (2005) Pivotal role of gp91phox-containing NADH oxidase in lipopolysaccharide-induced tumor necrosis factor-alpha expression and myocardial depression. Circulation 111(13):1637–1644PubMedCrossRef
52.
Zhu H, Shan L, Peng T (2009) Rac1 mediates sex difference in cardiac tumor necrosis factor-alpha expression via NADPH oxidase-ERK1/2/p38 MAPK pathway in endotoxemia. J Mol Cell Cardiol 47(2):264–274PubMedCrossRef
53.
Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayan N, Ren J (2006) Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch. Diabetologia 49(6):1434–1446PubMedCrossRef
54.
Guo Z, Xia Z, Jiang J, McNeill JH (2007) Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. Am J Physiol Heart Circ Physiol 292(4):H1728–H1736PubMedCrossRef
55.
Zima AV, Blatter LA (2006) Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 71(2):310–321PubMedCrossRef
56.
Yano M, Okuda S, Oda T, Tokuhisa T, Tateishi H, Mochizuki M, Noma T, Doi M, Kobayashi S, Yamamoto T, Ikeda Y, Ohkusa T, Ikemoto N, Matsuzaki M (2005) Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation 112(23):3633–3643PubMedCrossRef
57.
Palomeque J, Rueda OV, Sapia L, Valverde CA, Salas M, Petroff MV, Mattiazzi A (2009) Angiotensin II-induced oxidative stress resets the Ca2+ dependence of Ca2+-calmodulin protein kinase II and promotes a death pathway conserved across different species. Circ Res 105(12):1204–1212PubMedCrossRef
58.
Dorn GW 2nd (2009) Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res 81(3):465–473PubMedCrossRef
59.
Qin F, Patel R, Yan C, Liu W (2006) NADPH oxidase is involved in angiotensin II-induced apoptosis in H9C2 cardiac muscle cells: effects of apocynin. Free Radic Biol Med 40(2):236–246PubMedCrossRef
60.
Hayashi H, Kobara M, Abe M, Tanaka N, Gouda E, Toba H, Yamada H, Tatsumi T, Nakata T, Matsubara H (2008) Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res 31(2):363–375PubMedCrossRef
61.
Gilleron M, Marechal X, Montaigne D, Franczak J, Neviere R, Lancel S (2009) NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem Biophys Res Commun 388(4):727–731PubMedCrossRef
62.
Shen E, Li Y, Li Y, Shan L, Zhu H, Feng Q, Arnold JM, Peng T (2009) Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes 58(10):2386–2395PubMedCrossRef
63.
Thandavarayan RA, Watanabe K, Ma M, Gurusamy N, Veeraveedu PT, Konishi T, Zhang S, Muslin AJ, Kodama M, Aizawa Y (2009) Dominant-negative p38alpha mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am J Physiol Heart Circ Physiol 297(3):H911–H919PubMedCrossRef
64.
Sun Y (2007) Oxidative stress and cardiac repair/remodeling following infarction. Am J Med Sci 334(3):197–205PubMedCrossRef
65.
Fukui T, Yoshiyama M, Hanatani A, Omura T, Yoshikawa J, Abe Y (2001) Expression of p22-phox and gp91-phox, essential components of NADPH oxidase, increases after myocardial infarction. Biochem Biophys Res Commun 281(5):1200–1206PubMedCrossRef
66.
Krijnen PA, Meischl C, Hack CE, Meijer CJ, Visser CA, Roos D, Niessen HW (2003) Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol 56(3):194–199PubMedCrossRef
67.
Doerries C, Grote K, Hilfiker-Kleiner D, Luchtefeld M, Schaefer A, Holland SM, Sorrentino S, Manes C, Schieffer B, Drexler H, Landmesser U (2007) Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 100(6):894–903PubMedCrossRef
68.
Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, Marber M, Monaghan MJ, Shah AM (2008) Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 51(2):319–325PubMedCrossRef
69.
Frantz S, Brandes RP, Hu K, Rammelt K, Wolf J, Scheuermann H, Ertl G, Bauersachs J (2006) Left ventricular remodeling after myocardial infarction in mice with targeted deletion of the NADPH oxidase subunit gp91PHOX. Basic Res Cardiol 101(2):127–132PubMedCrossRef
70.
Dandapat A, Hu CP, Li D, Liu Y, Chen H, Hermonat PL, Mehta JL (2008) Overexpression of TGFbeta1 by adeno-associated virus type-2 vector protects myocardium from ischemia-reperfusion injury. Gene Ther 15(6):415–423PubMedCrossRef
71.
Matsushima S, Kinugawa S, Yokota T, Inoue N, Ohta Y, Hamaguchi S, Tsutsui H (2009) Increased myocardial NAD(P)H oxidase-derived superoxide causes the exacerbation of postinfarct heart failure in type 2 diabetes. Am J Physiol Heart Circ Physiol 297(1):H409–H416PubMedCrossRef
72.
Sadek MM, Haddad T, Haddad H (2009) The role of statins in chronic heart failure. Curr Opin Cardiol 24(2):167–171PubMedCrossRef
Metadata
Title
NADPH oxidases and cardiac remodelling
Authors
Adam Nabeebaccus
Min Zhang
Ajay M. Shah
Publication date
01-01-2011
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 1/2011
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-010-9186-2

Other articles of this Issue 1/2011

Heart Failure Reviews 1/2011 Go to the issue

OriginalPaper

Innate immunity and remodelling

OriginalPaper

Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities

EditorialNotes

Myocardial remodeling, an overview

OriginalPaper

TNFα in myocardial ischemia/reperfusion, remodeling and heart failure

OriginalPaper

Cellular and molecular pathways to myocardial necrosis and replacement fibrosis

OriginalPaper

STAT3 and cardiac remodeling

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits